A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
Completed
Supernus Pharmaceuticals, Inc.
Phase 1/Phase 2
2010-06-01
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and
tolerability study in adults with ADHD. The target subjects are healthy male or female adults
aged 18 to 64 years, inclusive, with a diagnosis of ADHD. A total of fifty subjects will be
enrolled at approximately 5 sites in the US. Subjects will be randomized (1:1) to one of two
treatment groups, SPN-812V or placebo.
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
Completed
Supernus Pharmaceuticals, Inc.
Phase 2
2016-02-01
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group,
dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release
Capsule) in children 6-12 years of age with ADHD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
